Cerebrolysin vs LL-37
Overview
Cerebrolysin and LL-37 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Cerebrolysin and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Cerebrolysin | LL-37 | |
|---|---|---|
| Category | Pain Management | Pain Management |
| Regulatory status (US) | Research use only | Compounding (Rx) — Apr 2026 |
| Typical dosage | 5-10 ml | 2-5 mg |
| Frequency | multiple weekly | twice weekly |
| Reported benefits | Nerve pain reduction, neuroprotection, stroke pain support | Inflammation-related pain relief, infection-related pain support |
| Reported side effects | Generally well-tolerated | Generally safe |
Key differences
Primary use. Cerebrolysin is categorised under Pain Management, while LL-37 falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Cerebrolysin: not FDA-approved; treated as a research compound. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Cerebrolysin is typically dosed at 5-10 ml (multiple weekly). LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Cerebrolysin and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Cerebrolysin and LL-37?
- Cerebrolysin and LL-37 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. Cerebrolysin is not FDA-approved; generally classified as a research compound, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Cerebrolysin used for?
- Neuropathic pain support.
- What is LL-37 used for?
- Inflammatory pain modulation.
- Can you take Cerebrolysin and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Cerebrolysin and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Cerebrolysin or LL-37 FDA-approved?
- Cerebrolysin is not FDA-approved; generally classified as a research compound. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Cerebrolysin — full monograph: mechanism, research, dosing & references
- LL-37 — full monograph: mechanism, research, dosing & references